Shoulder Innovations is an IPO to watch, this analyst says

Roth Capital Markets analyst Jason Wittes noted in a July 28 pre-IPO report that Shoulder Innovations, a new entrant in the $2.8-billion shoulder replacement market, officially launched its IPO roadshow last week and is expected to price on July 30 after market close.

The company’s IPO pricing range of $19 to $21 per share implies a market capitalization between approximately $430.1-million and $475.4-million, assuming 22.6 million fully diluted shares at the top end. The gross offering size is estimated at $120.8-million, with expected net proceeds of $80-million, or $102-million if underwriters exercise the overallotment option in full, based on a midpoint share price of $20.

Wittes noted that Roth is not participating in the offering or initiating formal coverage.

“The net proceeds are intended to be used to scale up the company’s commercial organization through the hiring of additional sales representatives and expansion of its commercial leadership team, as well as investing in additional instrument sets, to fund the research and development of continued general innovation in its implant systems, and for working capital and other general corporate purposes,” he said. “We watched SI’s roadshow and were impressed by the company’s novel approach to improving the $2.8-billion shoulder replacement market with design and workflow improvements.”

Shoulder Innovations, founded in 2009 and based in Grand Rapids, Michigan, develops next-generation shoulder replacement implants aimed at improving surgical planning, implant performance, and procedural efficiency. The company distributes its implants across the U.S. through a mix of in-house and contracted sales reps, with manufacturing handled by third-party partners.

Shoulder Innovations is planning an IPO offering of five million shares, with a 15% overallotment option. The expected price range of $19 to $21 per share implies a market cap between approximately $430.1-million and $475.4-million, and an enterprise value ranging from $438.5-million to $483.8-million. Assuming pricing at the high end, the company anticipates receiving about $107.5-million in net proceeds after underwriting discounts and commissions. Key pre-IPO shareholders include USVP Management (14.6%), Aperture Venture Partners (11.6%), Glide Healthcare Partners (11.3%), and Gilmartin Capital (11.6%).

The company expects trailing twelve-month revenue to reach $37.3-million by the end of Q2 2025, with estimated Q2 revenue of around $11.0-million, up 33.4% year-over-year from approximately $8.3-million in Q2 2024. Gross margin for the first half of 2025 is projected to hold steady at 77%. Estimated expenses include $1.3–$1.5-million in R&D and $13.4–$13.9-million in SG&A. Shoulder Innovations forecasts a net loss of $19.1–$21.1-million, including $12.2–$14.2-million in non-cash charges related to preferred stock warrant liabilities and Series E options. Adjusted EBITDA loss is expected to fall between $18-million and $20-million.

“We anticipate larger players will eventually be able to redesign their implants to better address the shortcomings of their reverse shoulders, but this appears several years out,” Wittes said. “Robotics are being introduced into the market, and we think SI will eventually need to respond, but based on the adoption curves for robotics in spine and large joints, we anticipate this will take at least five years before it becomes relevant, especially with capital and space-constrained ASCs.

“While the company has minimized its tool cost to lower its capital expenditure outlay, we still expect a slow ramp to profitability, given heavy sales and marketing expenses required to build market share. This may delay profitability despite strong high 70’s% gross margins.

“The company has made it clear that it looks to diversify into adjacent sports medicine opportunities, which while promising, may prolong the ramp to profitability.”

-30-